A KRAS-targeting drug excites, but has blemishes

Amgen’s KRAS-blocking drug has generated excitement among cancer researchers and investors alike, thanks to its tumor-shrinking capabilities for lung cancer.

Yesterday, the company unveiled new data for AMG510 that continues to indicate about half the tested patients are responsive. The potential “sort of blows you away,” one top pulmonologist told STAT’s Adam Feuerstein. Another considered Amgen’s work “the most exciting presentation” coming out of this past week’s World Conference on Lung Cancer.

But although the data are encouraging, they present a whole new set of questions that may temper some of the enthusiasm around the drug.

Read more.